Short-term Outcomes of Pancreatectomy in Congenital Hyperinsulinism: A Retrospective Multi-center Study

Document Type : Original Article


1 Pediatric Surgery Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Department of Surgery, Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran

3 Department of Pediatric Surgery, Abouzar Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahwaz, Iran

4 Mardani Azar Pediatric Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

5 Neonatal Health Research Center, Mofid Children’s Hospital, Shahid Beheshti Medical University of Medical Sciences, Tehran, Iran


Background: Congenital hyperinsulinism (CH) is a well-known cause of the persistent neonatal hypoglycemic state that may lead to irreversible neurological damage. While medical therapy can improve the condition in some cases, refractory cases require further investigation to identify focal or diffuse pancreatic lesions. Surgery is the main treatment for refractory cases and can improve the neurological and glycemic status of patients. The study aimed to evaluate the short-term outcomes of surgical intervention in cases of CH who underwent surgical treatment.
Methods: A multicenter cross-sectional survey was conducted to review cases of CH that underwent surgery between 2018 and 2020. Focal cases were treated with simple enucleation or distal pancreatectomy, while diffuse cases underwent near-total pancreatectomy. The glycemic and neurological states of the patients were evaluated and the results were analyzed.
Results: Among the 56 neonates who underwent pancreatic surgery, 48 (85%) had diffuse disease, and the remaining cases suffered from focal lesions. All focal cases achieved normoglycemia, while 24 (50%) of the diffuse cases achieved normal glycemic levels (P≤0.003). Additionally, the incidence of irreversible neurological deficits was higher in the diffuse group (P=0.029).
Conclusion: The focal form of CH seems to be totally curative by surgical operations. However, the proper management of diffuse form is still demanding. Although in our study, we had an acceptable success rate in the short-term, lifelong euglycemia may not be obtainable in these patients.


  1. Demirbilek H, Hussain K. Congenital hyperinsulinism: diagnosis and treatment update. J Clin Res Pediatr Endocrinol. 2017; 9(2):69-87.
  2. 2Banerjee I, Raskin J, Arnoux JB, De Leon DD, Weinzimer SA, Hammer M, et al. Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families. Orphanet J Rare Dis. 2022; 17(1):1-12.
  3. Rosenfeld E, Ganguly A, De Leon DD. Congenital hyperinsulinism disorders: genetic and clinical characteristics. American Journal of Medical Genetics Part C: Seminars in Medical Genetics; 2019.
  4. Adzick NS, De Leon DD, States LJ, Lord K, Bhatti TR, Becker SA, et al. Surgical treatment of congenital hyperinsulinism: results from 500 pancreatectomies in neonates and children. J Pediatr Surg. 2019; 54(1):27-32.
  5. Seetharaman SS, Topor LS. 50 Years Ago in The Journal of Pediatrics: Differentiating Focal Versus Diffuse Hyperinsulinism. J Pediatr. 2022; 244:85.
  6. Rozance PJ, Hay WW. New approaches to management of neonatal hypoglycemia. Matern Health Neonatol Perinatol. 2016;2(1):1-7.
  7. Thornton PS, Stanley CA, De Leon DD, Harris D, Haymond MW, Hussain K, et al. Recommendations from the Pediatric Endocrine Society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. J Pediatr. 2015; 167(2):238-45.
  8. Worth C, Yau D, Salomon Estebanez M, O’shea E, Cosgrove K, Dunne M, et al. Complexities in the medical management of hypoglycaemia due to congenital hyperinsulinism. Clin Endocrinol. 2020;92(5):387-95.
  9. Laje P, States LJ, Zhuang H, Becker SA, Palladino AA, Stanley CA, et al. Accuracy of PET/CT scan in the diagnosis of the focal form of congenital hyperinsulinism. J Pediatr Surg. 2013; 48(2):388-93.
  10. Yorifuji T, Horikawa R, Hasegawa T, Adachi M, Soneda S, Minagawa M, et al. Clinical practice guidelines for congenital hyperinsulinism. Clin Pediatr Endocrinol. 2017; 26(3):127-52.
  11. Glaser B, Blech I, Krakinovsky Y, Ekstein J, Gillis D, Mazor-Aronovitch K, et al. ABCC8 mutation allele frequency in the Ashkenazi Jewish population and risk of focal hyperinsulinemic hypoglycemia. Genet Med. 2011;13(10):891-4.
  12. Galcheva S, Demirbilek H, Al-Khawaga S, Hussain K. The Genetic and molecular mechanisms of congenital hyperinsulinism. Front Endocrinol. 2019; 10:111.
  13. Avatapalle HB, Banerjee I, Shah S, Pryce M, Nicholson J, Rigby L, et al. Abnormal neurodevelopmental outcomes are common in children with transient congenital hyperinsulinism. Front Endocrinol. 2013; 4:60.
  14. Ferrara C, Patel P, Becker S, Stanley CA, Kelly A. Biomarkers of insulin for the diagnosis of hyperinsulinemic hypoglycemia in infants and children. J Pediatr. 2016; 168:212-9.
  15. Blomberg BA, Moghbel MC, Saboury B, Stanley CA, Alavi A. The value of radiologic interventions and 18F-DOPA PET in diagnosing and localizing focal congenital hyperinsulinism: systematic review and meta-analysis. Mol Imaging Biol. 2013;
  16. Hawkes CP, Lado JJ, Givler S, et al. The effect of continuous intravenous glucagon on glucose requirements in infants with congenital hyperinsulinism. JIMD Reports: Springer; 2018.
  17. Herrera A, Vajravelu ME, Givler S, Mitteer L, Avitabile CM, Lord K, et al. Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide. J Clin Endocr. 2018; 103(12):4365-72.
  18. Keyes ML, Healy H, Sparger KA, Orth LE, Geha M, Roumiantsev S, et al. Necrotizing enterocolitis in neonates with hyperinsulinemic hypoglycemia treated with diazoxide. Pediatrics. 2021; 147(2).
  19. Theodorou CM, Hirose S. Necrotizing enterocolitis following diazoxide therapy for persistent neonatal hypoglycemia. J Pediatr Surg Case Rep. 2020; 52:101356.
  20. Cao B, Wu D, Su C, Chen J, Liang X, Liu M, et al. Efficacy and safety of octreotide treatment for diazoxide-unresponsive congenital hyperinsulinism in China. Pediatr Investig. 2020; 4(01):29-36.
  21. Cuff H, Lord K, Ballester L, Scully T, Stewart N, De Leon DD. The Use of Lanreotide in the Treatment of Congenital Hyperinsulinism. J Clin Endocr. 2022; 107(8):e3115-20.
  22. Lord K, Dzata E, Snider KE, Gallagher PR, De León DD. Clinical presentation and management of children with diffuse and focal hyperinsulinism: a review of 223 cases. J Clin Endocr. 2013; 98(11):1786-9.
  23. Beltrand J, Caquard M, Arnoux JB, Laborde K, Velho G, Verkarre V, et al. Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism. Diabetes Care. 2012; 35(2):198-203.